Tongana nyen ti sava kobela ti cancer ti prostate?
A yeke wara akode nde nde ti kaïngo na cancer ti prostate, na a yeke bâ nga na lege wa kobela ni ayeke gue na li ni nga wala kobela ni ayeke ngangu mingi.
Ambeni kode ti kaïngo kobela ni ayeke so:
1. Ti bâ ndo nzoni: A hunda ti bâ lege ti kobela ni nzoni na lege ti gingo nda ti ye lakue, ahon ti to nda ti kaïngo ni hio.
A lingbi ti sala kusala na ni teti akoli so ayeke na kpale ti kobela ti cancer ti prostate mingi pëpe.
2. Kode ti salango opération: A yeke lungula ye so ayeke na yâ ti da ti koli ti sala kusala na ni ti lungula ye so ayeke na yâ ti da ti koli.
A lingbi ti sala ni na lege ti opération so a zi yâ ni pëpe wala na laparoscopie (na salango kusala na akete lê ti kä nga na agbakuru so ayeke nde).
3. Kode ti kaïngo kobela ti cancer na lege ti sungo ti lumière: Kode ti kaïngo kobela so ayeke mû ngangu ti wâ ti wâ ti fâ na acellule ti cancer.
A lingbi ti yôro yorö ni na yâ ti mbeni masini so ayeke na gigi ti tele ti zo, wala a lingbi ti yôro ni na yâ ti mbeni ye so ayeke na tele ti zo ni, so a zia ni ndulu na cancer ni.
4. Kode ti kaïngo kobela ti cancer ti prostate: Kode ti kaïngo kobela so ayeke sala si yâ ti tele ti zo akiri na peko kete wala a kaï biani biani maïngo ti cancer ti prostate.
A lingbi ti sala kusala na ni gi lo oko wala legeoko na ambeni yorö nde.
5. Kode ti kaïngo kobela ti cancer: Kode ti kaïngo kobela so ayeke sala kusala na ayorö ti fâ na acellule ti cancer.
A lingbi ti mû ni ti kaï na kobela ti cancer ti prostate so ague na li ni mingi na so amû ambeni mbage ti tele ti zo.
6. Kode ti kaïngo kobela ti cancer: Kode ti kaïngo kobela so ayeke mû maboko na mbeni mbage ti tele ti zo ti tiri na kobela ti cancer.
A lingbi ti mû ni ti kaï na kobela ti cancer ti prostate so ague na li ni mingi na so ambeni yorö nde asala kusala na ni pëpe.
7. Kode ti kaïngo kobela so a zia ambeni ye nde na tele ni: Kode ti kaïngo kobela so ayeke gi ti sala ngangu na ndo ambeni ye so ayeke na yâ mênë ti zo, so ayeke mû maboko na acellule ti cancer ti maï na ti ngbâ na fini.
A lingbi ti mû ni ti kaï na kobela ti cancer ti prostate so ague na li ni mingi na so ambeni yorö nde asala kusala na ni pëpe.
8. Kode ti kaïngo kobela ti cancer na lege ti dê: Kode ti kaïngo kobela so ayeke sala kusala na ngangu dê ti kanga na ti fâ acellule ti cancer.
A lingbi ti mû ni ti kaï na kobela ti cancer ti prostate so ade ti mû kobela mingi pëpe wala so akiri aga ngangu na peko ti ambeni kode ti kaïngo na kobela ni.
9. A yeke sala kusala na mbeni kode so a hiri ni ultrason (HIFU): Kode ni so ayeke sala kusala na amapo ti go so ayeke toto ngangu mingi ti gboto wâ na yâ ti acellule ti cancer na ti futi ni.
A lingbi ti mû ni ti kaï na kobela ti cancer ti prostate so ade ti mû kobela mingi pëpe wala so akiri aga ngangu na peko ti ambeni kode ti kaïngo na kobela ni.
10. Ti bâ ndo nzoni: Kode so ahunda ti bâ lege ti kobela ni nzoni na lege ti gingo nda ti ye lakue, me ti to nda ti kaïngo kobela ni pëpe gi tongana afä ni asigigi wala agbian.
A lingbi ti sala kusala na ni teti akoli so ngu ti ala ague na li ni mingi pëpe, so ayeke na cancer ti prostate so ayeke maï yeke yeke nga na ambeni kpale ti seni so ayeke ngangu.
A yeke kota ye ti tene mo na awanganga asara lisoro na ndo ti akode nde nde so mo lingbi ti sara na kua ti mo ti wara yorö so ayeke nzoni mingi teti mo oko oko kue.
Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y, Xu C: Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 2021, 178 (2): 239-261.
Talkar SS, Patravale VB: Gene Therapy for Prostate Cancer: A Review. Endocr Metab Immune Disord Drug Targets. 2021, 21 (3): 385-396.
Šamija I, Fröbe A: CHALLENGES IN MANIPULATING IMMUNE SYSTEM TO TREAT PROSTATE CANCER. Acta Clin Croat. 2019, 58 (Suppl 2): 76-81.
Akaza H, Hinotsu S, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Hirao Y, Murai M, Yamanaka H, Namiki M: The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J Urol. 2006, 176 (6 Pt 2): S47-9.
Abraham-Miranda J, Awasthi S, Yamoah K: Immunologic disparities in prostate cancer between American men of African and European descent. Crit Rev Oncol Hematol. 2021, 164 (): 103426.
de Vrij J, Willemsen RA, Lindholm L, Hoeben RC, Bangma CH, Barber C, Behr JP, Briggs S, Carlisle R, Cheng WS, Dautzenberg IJ, de Ridder C, Dzojic H, Erbacher P, Essand M, Fisher K, Frazier A, Georgopoulos LJ, Jennings I, Kochanek S, Koppers-Lalic D, Kraaij R, Kreppel F, Magnusson M, Maitland N, Neuberg P, Nugent R, Ogris M, Remy JS, Scaife M, Schenk-Braat E, Schooten E, Seymour L, Slade M, Szyjanowicz P, Totterman T, Uil TG, Ulbrich K, van der Weel L, van Weerden W, Wagner E, Zuber G: Adenovirus-derived vectors for prostate cancer gene therapy. Hum Gene Ther. 2010, 21 (7): 795-805.
Lee E, Ha S, Logan SK: Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells. PLoS One. 2015, 10 (10): e0141589.
['Tënë ti ziango kamene na lê: tënë ti seni']
['A zia site so gi ti fa na ye na azo na ti mû wango na ala.']
['A lingbi a sala kusala pëpe na asango so a mû ti hinga wala ti kaï na mbeni kpale ti seni wala kobela, na a lingbi ala so aye ti wara wango ti kaïngo kobela teti ala mveni ahunda mbeni wanganga so ayeke na mbeti ti hinga ye na ndo ni.']
['Bâ so tongana a hunda na zo ti fa wungo ti azo so ayeke na mbeni kobela, a yeke ngangu ti tene lo fa tâ wungo ti azo ni.']
['Gi lakue wango ti wanganga ti mo wala mbeni wanganga so ahinga kua ti lo nzoni na ndo ti kobela ti mo. Zia lâ oko pëpe ti ke wango ti wanganga wala ti ku ti wara ni ndali ti mbeni ye so mo diko na ndo ti site so. Tongana mo bâ so mo yeke na yâ ti mbeni kpale ti seni, iri 911 wala gue hio na hôpital so ayeke nduru na mo.']
['Kengo tene: droit ti lo ti sala tene']
['Ndia ti Amerika na ndo droit ti sigingo na ambeti (Digital Millennium Copyright Act) ti ngu 1998, 17 U.S.C. § 512 (so a hiri ni DMCA) amû lege na azo so ayeke na droit ti sigingo na ambeti ti bâ wala ambeti so asigigi na ndo ti Internet ni adoro droit ti ala so ndia ti Amerika amû na ndo droit ti sigingo na ambeti amû lege na ala ti sala ni. ']
['Tongana mo pensé so mbeni ye so ayeke na ndo ti site ti e wala na yâ ti ambeni ye so e yeke sara andu droit ti mo ti batango ambeti ti e, mo (wala zo so mo sara kua na iri ti lo) alingbi ti tokua na e mbeni mbeti ti hunda ti tene a zi ni wala a kanga lege na mo ti wara ni.']
['A lingbi a tokua ambeti ni na lege ti mbeni lettre so a sû na ndo ti ordinateur wala na lege ti mbeni téléphone (bâ mbage "A-adresse ti téléphone").']
['Ndia ti DMCA ahunda ti tene na yâ ti mbeti ti mo so a tene mbeni zo asara mbeni ye so ake ndia ti droit ti batango ambeti, mo zia atënë so ge: (1) fango peko ti kua so ndia ti batango ambeti ni ake ni; (2) fango peko ti aye so a tene a sara ye ti ke ndia ti batango ambeti ni nga na atënë so alingbi ti mû lege na e ti wara aye ni so; (3) asango ti mo ti wara mo, so andu adresse ti mo, numéro ti téléphone ti mo nga na adresse ti e-mail ti mo; (4) mbeni tënë so mo tene na bê ti mo kue so tënë ti aye ni so mo dema tere dä so ayeke pëpe tënë ti zo so ayeke na droit ti batango ambeti ni, wala zo so ayeke sara kua na iri ti lo, wala ndia ti kodoro ti mo.']
['(5) Mo sû maboko ti mo na gbe ti ngbanga ti mvene na mo tene so atënë so ayeke na yâ ti mbeti ni ayeke tâ tënë nga so mo yeke na ngangu ti sara si a bata droit ti mo ti sigingo na ambeti so a tene a doro ni.']
['Nga (6) mbeni maboko ti zo so ayeke na droit ti sigingo na ambeti ni wala mbeni maboko ti mbeni zo so ayeke sara kua na iri ti zo ni.']
['Tongana mo sû atënë so kue pëpe, a lingbi ti sara si a mû ngoi mingi pëpe ti bâ lege ti tënë ti mo ni.']
['Tënë ti kiri ti bâ zo']
['Tongana mo yeke na mbeni hundango tënë wala mbeni tënë ti tene, tokua ni na e na lege ti mbeni lettre.']
How to treat prostate cancer?
There are several treatment options available for prostate cancer, depending on the stage and aggressiveness of the cancer, as well as the patient's overall health and personal preferences.
Some common treatments include:
1. Active surveillance: This approach involves closely monitoring the cancer with regular checkups and tests, rather than immediately starting treatment.
It may be suitable for men with low-risk prostate cancer.
2. Surgery: A prostatectomy is a surgical procedure to remove the prostate gland.
It can be done through open surgery or laparoscopically (using small incisions and specialized tools).
3. Radiation therapy: This treatment uses high-energy radiation to kill cancer cells.
It can be delivered externally (from a machine outside the body) or internally (through implants placed near the tumor).
4. Hormone therapy: This treatment reduces the levels of male hormones (androgens) in the body, which can slow or stop the growth of prostate cancer.
It can be used alone or in combination with other treatments.
5. Chemotherapy: This treatment uses drugs to kill cancer cells.
It may be used for advanced prostate cancer that has spread to other parts of the body.
6. Immunotherapy: This treatment helps the immune system fight cancer.
It may be used for advanced prostate cancer that has not responded to other treatments.
7. Targeted therapy: This treatment targets specific genes or proteins that help cancer cells grow and survive.
It may be used for advanced prostate cancer that has not responded to other treatments.
8. Cryotherapy: This treatment uses extreme cold to freeze and kill cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
9. High-intensity focused ultrasound (HIFU): This treatment uses high-frequency sound waves to heat and destroy cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
10. Watchful waiting: This approach involves closely monitoring the cancer with regular checkups and tests, but not starting treatment unless symptoms appear or change.
It may be suitable for older men with slow-growing prostate cancer and other serious health conditions.
It is important to discuss all treatment options with a healthcare team to determine the best course of action for each individual case.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Na ndo ni']
['Na yâ ti BioMedLib, a yeke sala kusala na a-ordinateur so ayeke sala kua gi na ndo ti tele ti ala mveni (na lege ti kode ti mandango ye na lege ti masini) ti leke ahundango tënë na akiringo tënë so a zia na tele ti mba.']
['E to nda ni na ambeti ti senda-ye kutu 35 so ayeke na yâ ti ambeti-sango so a iri ni PubMed/Medline nga na ambeni site ti e so a iri ni RefinedWeb.']
